Novartis Pharmaceuticals Corp., of East Hanover, N.J., part of Novartis AG, said the FDA approved Signifor long-acting release (pasireotide) for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.